Cover Image
市場調查報告書

細菌性皮膚·皮膚結構感染疾病(SSSI):開發中產品分析

Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 271820
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
細菌性皮膚·皮膚結構感染疾病(SSSI):開發中產品分析 Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2014
出版日期: 2014年11月18日 內容資訊: 英文 44 Pages
簡介

本報告提供全球細菌造成的皮膚·皮膚結構感染疾病(SSSI)治療藥的開發趨勢調查,提供開發中產品各開發階段的比較分析,藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,再加上這個部門的最新趨勢,主要企業的檢討等。

簡介

  • 調查範圍

細菌造成的皮膚·皮膚結構感染疾病(SSSI)概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

細菌性皮膚·皮膚結構感染疾病(SSSI):企業開發中的治療藥

細菌性皮膚·皮膚結構感染疾病(SSSI):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

細菌性皮膚·皮膚結構感染疾病(SSSI):企業開發中的產品

開發細菌性皮膚·皮膚結構感染疾病(SSSI)治療藥的企業

  • GlaxoSmithKline plc
  • Melinta Therapeutics, Inc
  • Paratek Pharmaceuticals, Inc.
  • Debiopharm International S.A.
  • MerLion Pharmaceuticals Pte Ltd
  • Nabriva Therapeutics AG
  • Cempra, Inc.
  • Cellceutix Corporation
  • Tetraphase Pharmaceuticals Inc.
  • Durata Therapeutics, Inc.
  • Furiex Pharmaceuticals, Inc.
  • Microbion Corporation
  • Dong-A Socio Holdings Co Ltd

細菌性皮膚·皮膚結構感染疾病(SSSI):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • dalbavancin
  • tedizolid phosphate
  • omadacycline tosylate
  • delafloxacin
  • GSK-1322322
  • AFN-1252
  • brilacidin
  • BC-3781
  • fusidic acid
  • avarofloxacin hydrochloride
  • eravacycline
  • GSK-2140944
  • BC-7013
  • Bismuth ethanedithiol
  • AFN-1252
  • DBAF-101
  • finafloxacin

細菌性皮膚·皮膚結構感染疾病(SSSI):最近的開發平台趨勢

細菌性皮膚·皮膚結構感染疾病(SSSI):暫停中的計劃

細菌性皮膚·皮膚結構感染疾病(SSSI):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5701IDB

Summary

Global Markets Direct's, 'Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2014', provides an overview of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Skin And Skin Structure Infections (SSSI) Caused By Bacteria
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria Overview
  • Therapeutics Development
    • Pipeline Products for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Overview
    • Pipeline Products for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Therapeutics under Development by Companies
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Products under Development by Companies
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Companies Involved in Therapeutics Development
    • Furiex Pharmaceuticals, Inc.
    • Nabriva Therapeutics AG
    • Tetraphase Pharmaceuticals Inc.
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acorafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-3781 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IOG-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • siderocillin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Recent Pipeline Updates
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H2 2014
  • Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Comparative Analysis by Unknown Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Nabriva Therapeutics AG, H2 2014
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Recent Pipeline Updates, H2 2014
  • Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H2 2014
  • Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top